{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-003248","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.840201+00:00","generated_at":"2026-05-17T08:22:27.824510+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silexion selects CRO AMS for SIL204 Phase 2/3 trials; H1 2026 start expected","bullets":["CRO AMS has over 28 years of drug development experience and Phase 3 oncology trial expertise.","Regulatory submissions planned for Q4 2025 (Israel) and Q1 2026 (EU).","Phase 2/3 clinical trials for SIL204 expected to commence in first half of 2026.","SIL204 previously showed up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutations."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-003248","json":"https://secwatch.observer/filing/0001178913-25-003248.json","markdown":"https://secwatch.observer/filing/0001178913-25-003248.md","text":"https://secwatch.observer/filing/0001178913-25-003248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003248/0001178913-25-003248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003248/zk2533756.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:22:27.824510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}